L
Lisa M. Allinson
Researcher at University of Leeds
Publications - 4
Citations - 53
Lisa M. Allinson is an academic researcher from University of Leeds. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 2, co-authored 3 publications receiving 35 citations.
Papers
More filters
Journal ArticleDOI
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
Ashleigh Herriott,Susan J. Tudhope,Gesa Junge,Natalie Rodrigues,Miranda J. Patterson,Laura Woodhouse,John Lunec,Jill E. Hunter,Evan A. Mulligan,Michael Cole,Lisa M. Allinson,Jonathan P. Wallis,Scott Marshall,Evelyn Wang,Nicola J. Curtin,Elaine Willmore +15 more
TL;DR: PARP activity is highly variable in CLL and correlates with stress-induced proteins, and Proliferating CLL cells (including those with p53 or ATM loss) are highly sensitive to the PARP inhibitor talazoparib.
Journal ArticleDOI
Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer.
Waleed S. Al Amri,Lisa M. Allinson,Diana E. Baxter,Sandra M. Bell,Andrew M. Hanby,Andrew M. Hanby,Stacey J. Jones,Abeer M Shaaban,Lucy F. Stead,Eldo T. Verghese,Thomas A. Hughes +10 more
TL;DR: It is concluded that therapy-driven selection of somatic variants allows identification of chemotherapy response genes and in vitro knockdown data concerning drug sensitivity, and survival analysis of expression levels in patient cohorts all define the genes as mediators of and predictive markers for chemotherapy response in breast cancer.
Journal ArticleDOI
MiR-195 and Its Target SEMA6D Regulate Chemoresponse in Breast Cancer
Diana E. Baxter,Lisa M. Allinson,Waleed S. Al Amri,James A. Poulter,Arindam Pramanik,James L. Thorne,Eldo T. Verghese,Thomas A. Hughes +7 more
TL;DR: In this article, microRNAs and their targets influence chemoresponse, allowing the identification of SEMA6D as a predictive marker for chemotherapy response that could be used to direct therapy or as a target in chemosensitisation strategies.
Journal ArticleDOI
Loss of ALK hotspot mutations in relapsed neuroblastoma
Lisa M. Allinson,Aaron Potts,Angharad Goodman,Nick Bown,Matthew Bashton,D. Thompson,Nermine O. Basta,Alem S. Gabriel,Michael McCorkindale,Antony Ng,Richard J. Q. McNally,Deborah A. Tweddle +11 more
TL;DR: These are the first reported cases of loss of ALK mutations at relapse in neuroblastoma in the absence ofALK inhibitor therapy, reflecting intra‐tumoral spatial and temporal heterogeneity.